Genetic Variant in SLCO1B1 Linked to ACE Inhibitor-Induced Cough in Hypertensive Patients

A study conducted in Pakistan has identified a significant genetic variant in the SLCO1B1 gene that may predict the risk of angiotensin-converting enzyme inhibitor (ACEI)-induced cough in hypertensive patients. 
This discovery sheds light on the role of genetic predisposition in the adverse effects of widely prescribed ACE inhibitors, used for managing cardiovascular risk.
The study involved 74 hypertensive patients treated with ACEIs, of which 51% reported experiencing a persistent cough. Researchers conducted partial sequencing of the SLCO1B1 gene to identify single nucleotide polymorphisms (SNPs) and haplotypes associated with the cough. 
Among the findings, haplotype H4 showed a significant association with ACEI-induced cough, even after adjusting for sex and smoking status.
While six different SNPs and nine haplotypes were identified, only H4 emerged as a strong predictor for cough, highlighting its potential clinical significance. The study underscores the need for further validation in larger, more diverse cohorts to solidify SLCO1B1 as a genetic marker for ACEI intolerance. 
If confirmed, this genetic insight could enhance personalized medicine approaches, enabling healthcare providers to predict and mitigate the risk of ACEI-induced cough in susceptible individuals.